logo
logo

CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

Mar 01, 2021•over 4 years ago

Amount Raised

$59 Million

Round Type

series b

Philadelphia

Description

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA's total capital raised to date to nearly $121 million.

Company Information

Company

Carisma Rapeutics .

Location

Philadelphia, Pennsylvania, United States

About

CARISMA Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People